Judith S. Hochman, MD

Medicine (Cardiology), Program Co-Director, Primary Mentor

Dr Hochman has a particular interest in acute coronary syndromes, including the study of optimal management strategies, sex differences in pathophysiology and response to treatment, and cardiogenic shock. She developed, organized, was awarded NHLBI funding for, and was the Study Chair and Director of the Clinical Coordinating Center SHOCK Trial and Registry. The SHOCK Trial demonstrated the survival benefit of early revascularization for cardiogenic shock due to LV failure complicating myocardial infarction; these results led directly to revisions of the ACC/AHA Guidelines on the management of myocardial infarction. She also developed, organized, and was Study Chair for the first phase 2 and phase 3 multicenter randomized trials conducted to test a pharmacologic agent, a nitric oxide synthase inhibitor, for cardiogenic shock complicating acute MI (SHOCK 2 and TRIUMPH). Dr. Hochman also developed and led an NHLBI-funded international trial of late angioplasty/stenting after myocardial infarction, the Occluded Artery Trial (OAT). She is Study Chair and PI of OAT and directs the Clinical Coordinating Center at NYU involving over 200 sites, five core laboratories and other coordinating centers around the world. The results, which demonstrated no benefit for late angioplasty for persistent total occlusion late post MI and a trend toward excess reinfarction, were reported in the NEJM, and have resulted in new recommendations in the 2007 ACC/AHA guidelines on Unstable Angina/NSTEMI and ST Elevation Myocardial Infarction and the 2008 European Society of Cardiology Guidelines on STEMI. She has expertise in the investigation of novel anti-platelet and anticoagulant agent use in ACS and has served on the steering committee for numerous international clinical trials testing these agents.